Targeting T Cells to Treat Trypanosoma cruzi-Induced Myocarditis by Henriques-Pons, Andrea & Gomes, Marcelo P. Villa-Forte
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Targeting T Cells to Treat Trypanosoma cruzi-Induced
Myocarditis
Andrea Henriques-Pons and
Marcelo P. Villa-Forte Gomes




In 1995, the last World Health Organization (WHO)/International Society and Federation of
Cardiology (ISFC) Task Force on the definition and classification of cardiomyopathies defined
myocarditis (also named “inflammatory cardiomyopathy”) as an “inflammatory disease of the
myocardium associated with cardiac dysfunction” [1]. In myocarditis, the inflammatory
infiltrate of the myocardium is associated with necrosis and/or degeneration of adjacent
myocytes, which is not typical of – nor consistent with – myocardial ischemic damage seen
with coronary artery disease [1, 2]. The clinical presentation of myocarditis is dependent upon
the magnitude of myocardial inflammation, thus it may be quite variable. Clinical signs and
symptoms may range from subclinical disease (which may initially be unrecognized) to new-
onset acute heart failure or sudden death due to ventricular arrhythmias [3]. Moreover, the
clinical course of myocarditis may be as variable as its clinical presentations: some individuals
may develop acute myocarditis that resolves spontaneously within a few weeks, while others
may develop symptoms of chronic heart failure due to dilated cardiomyopathy (DCM) [3].
Although many patients with hemodynamically stable heart failure may respond well to
optimal medical therapy, a significant percentage of patients with DCM become medically
refractory and progress to irreversible end-stage heart failure for which heart transplantation
becomes the only hope of survival. Indeed, it is estimated that acute myocarditis resolves
completely in approximately 50% of cases, with an additional 25% of patients having incom‐
plete recovery (i.e.; partial normalization of cardiac function), while the remainder 25% will
inexorably progress to end-stage heart failure and death [1, 4-6].
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Despite its seemingly over simplistic definition, myocarditis is a disease with multiple
heterogeneous etiologies, which in turn lead to a highly variable and very complex pathology.
The etiologies of myocarditis can be divided into three groups: infective, immune-mediated
and toxic. Infective myocarditis may be bacterial (including gram-positive cocci, gram-
negative rods, gram-negative cocci, mycobacterium, mycoplasma); spirochetal (Borrelia,
Leptospira); fungal (including Aspergillus, Candida, Histoplasma and Cryptococcus, among
others); protozoal (including Trypanosoma cruzi, Toxoplasma gondii, Leishmania sp); parasitic
(Tenia solium, Echinococcus granulosus, Trichinella spiralis); rickettsial (e.g., Coxiella burnetii); and
viral (including adenovirus, influenza A and B, Coxsakievirus, poliovirus, HIV-1, herpes
simplex, and varicella-zoster, among many others). Immune-mediated myocarditis may be
due to allergens (tetanus toxoid, serum sickness, drugs such as penicillin, cephalosporins,
furosemide, isoniazide, tetracycline, among many others); alloantigens (as seen in heart
transplant rejection); and autoantigens such as “idiopathic” (or “virus-negative”) lymphocytic
and giant cell myocarditis, as well as “secondary”, i.e., associated with auto-immune disorders
such as systemic lupus erythematosus, vasculitides, rheumatoid arthritis, myasthenia gravis,
inflammatory bowel disease. Toxic myocarditis may be due to drugs (cocaine, ethanol, lithium,
cyclophosphamide, etc); heavy metals (copper, iron, lead); hormones (pheochromocytoma);
as well as miscellaneous etiologies such as radiation, certain spider or snake venoms, scorpion
sting, arsenic, and carbon monoxide [3].
This extraordinary multitude of ethiopathogenetic agents underscores the fact that proper and
accurate diagnosis of myocarditis at the tissue and molecular level is of utmost importance
because it may impact therapeutic choices as well as short- and long-term prognosis. Although
management of myocarditis should ideally consist of very specific and targeted therapeutic
strategies that go beyond symptomatic control of heart failure and temporary reversal of
cardiac dysfunction, such therapies are not clinically available for patients with most types of
myocarditis.
Myocarditis should be suspected on the basis of clinical presentation and imaging data, and
objective diagnosis should be made by endomyocardial biopsy (EMBx) using established
histological, immunological and immunohistochemical criteria combined with molecular
biological techniques, particularly polymerase chain reaction (PCR) and nested-PCR [1, 2, 7].
Histopathological analysis is essential to reach a classification of myocarditis based on
histological criteria (i.e., lymphocytic, giant cell, granulomatous, etc), while semi-quantitative
assessments of the specimens with regards to myocyte necrotic damage/inflammatory activity
(“grading”) and to measure the extension of fibrosis and architectural changes (“staging”) have
also been proposed [2]. Large panels of antibodies should be performed to characterize the
inflammatory cell population and the activated immunological processes. Immunohistochem‐
istry increases the sensitivity of EMBx, while amplification methods such as PCR are capable
of detecting few copy viral genomes even from an extremely small amount of tissue such as
an EMBx specimen [2]. A combination of these techniques will most likely reveal the patho‐
logical nature of myocarditis and help predict which patients may respond to immunomodu‐
latory therapies or not [8].
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2. Pathophysiology and ciinical presentation of Trypanosoma cruzi-
induced myocarditis
In the particular case of myocarditis induced by Trypanosoma cruzi infection, there is a distinct
disturbance in myocardial microcirculation with both vasoconstriction at the arteriolar level
and coronary vasodilation, as well as microaneurysm formation and ventricular fibrosis which
ultimately lead to congestive heart failure and ventricular arrhythmias [9]. Left ventricular
apical aneurysm is considered to be pathognomonic of Chagas disease, consisting of thinning
of the left ventricular apex, with a clear reduction of the myocardium due to fibrosis. Mural
thrombus is a frequent finding. Depending on the severity of cardiac dysfunction in infected
patients, the heart may maintain its normal volume or be mildly enlarged. However, patients
who die of chronic advanced or acute heart failure oftentimes have severe DCM with or
without hypertrophy and intramural thrombosis in the right atrium and left ventricular apex.
These patients usually have rounded hearts, venous congestion, and dilated chambers mainly
on the right side [10].
In this review we will focus on the importance of the acquired immune response to the control
of T. cruzi-induced myocarditis and discuss the possibility of targeting T cells to treat the
disease.
3. Trypanosoma cruzi infection
In 1909, Brazilian physician Carlos Chagas, M.D., identified a hemoflagellate parasite in a
child’s blood, leading to the discovery of the American Trypanosomiasis, or Chagas disease
(named in his honor). Dr. Chagas accomplished a unique feat in the history of medicine: not
only did he identify a new disease, but he also discovered the invertebrate vector and its
biological characteristics; isolated the causative agent – Trypanosoma cruzi (named in honor of
his mentor, Dr. Oswaldo Cruz) – and described its life cycle; identified the epidemiological
characteristics of the disease and its symptoms; and defined the disease’s diagnostic criteria.
Many years later, the disease was also found to be prevalent in many other Latin American
countries. Because the chronic manifestations of Chagas disease (particularly chronic heart
disease) affect patients in their most productive years of life, the disease carries a heavy social
and economic burden.
The disease can be transmitted by transplacental infection or during childbirth, organ trans‐
plantation, laboratory accidents with contaminated sharp objects, blood transfusion, or
ingestion of food or drink contaminated with infected vectors or their feces. During the process
of natural infection in endemic areas, T. cruzi parasites are transmitted by the infected feces of
blood-sucking reduviidae bugs, mainly Triatoma infestans and Rhodnius prolixus. These insects
typically live in poorly-constructed homes with cracks and crevices on the walls and roof, and
are very active at night, when they feed on human blood [11]. The bugs defecate while biting
exposed areas of the skin and, despite the injection of anesthetics and inhibitors of blood
clothing, the person instinctively smears the bug feces into the bite. The parasite then gains
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access to adjacent tissue through skin breaks or mucosal surfaces such as eyes and mouth.
Infective metacyclic trypomastigote forms invade macrophages and other cell types and
differentiate into proliferative amastigote forms [12]. These cytoplasmic forms differentiate
into trypomastigote forms that disrupt the host cell membrane and are free to be transported
by blood and infect other cells, such as cardiomyocytes.
The infection is followed by a typically benign acute-phase that lasts up to two months. In this
period, high numbers of circulating parasites are observed in blood. Symptoms, when present,
may include fever, headache, enlarged lymph nodes, pallor, muscle pain, difficulty in breath‐
ing, swelling and abdominal or chest pain. All patients will then enter a chronic phase, which
starts with a so-called “indeterminate” asymptomatic period. Most chronic patients will
remain asymptomatic throughout their lives. However, about 10% will develop digestive tract
(enlargement of the esophagus and/or colon, known as “megaesophagus” and “megacolon”),
neurological or mixed symptoms; and about 30% will develop Chagasic myocarditis, the most
common cause of death in infected patients [13].
Twenty years ago, the number of infected people was estimated at 16-18 million, with about
100 million people at risk of contracting the disease [14]. This dire epidemiological situation
has improved thanks mostly to a combined effort by many Latin American countries to control
the burden of transmission through insecticide spraying and serologic screening in blood
banks. Contemporary estimates indicate that approximately 10 million people are infected
with T. cruzi worldwide, and about 25 million people are considered at risk of contracting the
disease [15]. Despite the reduction in the number of infected people, the dynamic movement
of human populations from and to endemic areas in Latin America, the recrudescence of
vector-borne transmission, the risk for domestication of silvatic species of invertebrate hosts,
and the increased importance of secondary vector species still make the infection an imposing
challenge [14].
An important aspect of the infection in the current globalized world is the broader geographic
distribution of infected patients. In the last decades, many cases of Chagas disease were
reported in the USA, Canada, Europe and some Western Pacific countries. Most of those cases
were considered “imported” because they originated from infected Latin American immi‐
grants [16]. This changing geographical distribution highlights the increasing necessity to
heighten efforts to combat the spread of the disease and to develop new strategies to treat T.
cruzi-infected patients.
4. Pathogenesis of Trypanosoma cruzi-induced myocarditis
In the acute phase, many cardiomyocytes are parasitized [17]. This process typically occurs in
close proximity to extensive and diffuse inflammatory foci, which consists mostly of mono‐
nuclear cells. However, opposite to what is observed in the acute-phase of the disease, parasites
are much less frequently found in the heart of symptomatic chronic patients, despite the
persistence of extensive mononuclear inflammatory foci. Contrary to what was previously
hypothesized, chronic heart involvement in Chagas disease most likely does not rely on
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autoimmune mechanisms, but on parasites persistence [18]. However, the reason why most
patients will not develop chronic myocarditis and heart failure is unknown to this date. It is
postulated that the final outcome of the infection results from a complex and random combi‐
nation of pathological characteristics, including microcirculatory derangements; micro
ischemia; significant impairment of the autonomic nervous system due to ganglia cells death;
deregulation of the immune system balance; progressive cardiomyocytolysis induced by
parasite nests; individual genetic background; malnutrition; and comorbidities.
Experiments using murine infection and in vitro systems showed that the innate immune
response takes over the control of the infection shortly after the contact with the parasite, with
NK cells producing high levels of gamma interferon (IFN-γ), which then controls the early
replication of parasites in host cells [19]. Macrophages are very important to control the
infection, producing nitric oxide (NO) that limits the burden of intracellular parasites. Mast
cells are also very important in this scenario and we have recently published that infected CBA
mice treated with cromolyn, a mast cell stabilizer, have much greater parasitemia and IFN-γ
levels, and higher mortality rates, myocarditis, and cardiac damage [20].
With regards to acquired immunity, a number of published reports support the role and
importance of both CD4 and CD8 T cells in the control of the infection. Experimental ap‐
proaches can be used to deplete sub populations of lymphocytes, including the use of thy‐
mectomized mice; injection of neutralizing antibodies; or the infection of nude/nude mice
[21-23]. On the other hand, human data is based on the identification of T cell subsets in
postmortem specimens, which generally shows the predominance of CD8+ lymphocytes with
few macrophage-like, NK or plasma cells [24]. The predominance of CD8+ T cells starts in the
early acute-phase of the infection and extends to the chronic phase both in experimental models
and human patients. Although chronic T. cruzi-induced myocarditis seems to have a very
complex pathology, the immune system, especially CD8+ T lymphocytes, is considered a key
player in this condition. Despite many efforts, it is still not clear which cytotoxic cells and
molecular pathways employed by T lymphocytes may be contributing to the death of cardio‐
myocytes. We tested whether perforin, a major cytotoxic molecule employed by CD8+ T
lymphocytes, was important to the death of cardiomyocytes during the infection [25]. How‐
ever, we observed that the molecule was important for myocarditis control, because in the
absence of this cytotoxic pathway, cardiac cellular infiltration was much more intense, but
without increased signs of damage to myocytes. In this review, in this review we will sum‐
marize some data from the literature discerning biochemical pathways that target T lympho‐
cytes migration and their effector function in the myocardium, and the possibility of targeting
these cells to treat T. cruzi-induced myocarditis.
5. Treatment of T. cruzi infected patients
During the 1960s, two new drugs proved to be effective in vitro  and in vivo  in the treat‐
ment  of  Chagas  disease:  nifurtimox,  a  nitrofuran  [3-methyl-4-(5-itrofurfurilidenoamino)
tetrahydro-4H-1, 4-tiazin-1,1-dioxide, Bayer 2502]; and benznidazole [N-benzyl-2-nitroimi‐
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dazole acetamide,  RO 7-1051].  Although these drugs have been widely used since then,
therapeutic efficacy varies according to the phase of the disease (acute or chronic), duration
of treatment, patient’s age and geographical area of original infection [13]. The best results
are  obtained with  recently  infected  patients,  when cure  rates  of  60  to  80% can  be  ach‐
ieved, as opposed to cure rates no greater than 10% in chronic patients, depending on the
severity of cardiac dysfunction [26].
The side-effects of nifurtimox include anorexia, weight loss, insomnia, nausea, vomiting, and
others. Benznidazole-associated side-effects are classified in three types: (i) hypersensitivity
manifestations, such as dermatitis with cutaneous eruptions, periorbital or generalized edema,
fever, lymphadenopathy, and muscular and articular pain; (ii) depression of the bone marrow,
among which neutropenia, granulomatosis, and thrombocytopenic purpura: (iii) peripheral
polyneuropathy, in the form of paresthesia and polyneuritis.
More recently, new progenitor cell-based therapies have been developed with good and
promising results. In this therapy, total bone marrow cells are collected from individual
patients and a mononuclear cell-enriched preparation is slowly injected into the left and right
coronary systems. No adverse effects have been described with this procedure [27] and a few
months after treatment some patients had improved cardiac function. However, it is still
necessary to characterize the phenotype of the transferred cells and the mechanisms underly‐
ing such improvement in cardiac function.
The lack of effective treatments for most chronic symptomatic patients reinforces the need for
new drugs and strategies for treating T. cruzi infected patients. This could include the devel‐
opment of anti-parasite drugs based on the elucidation of biochemical pathways of the parasite
and/or on particular aspects of the immune response triggered by the infected host.
6. Molecular therapies
Advances in basic research that focus on interconnected molecular pathways in the immune
system led to the design of more specific therapeutic strategies. Many autoimmune and
inflammatory diseases can be treated using humanized or fully human-derived antibodies;
fusion proteins targeting co-stimulatory molecules; or injection of competitive ligands.
Neutralization of molecules involved in endothelial transmigration (CD11a/CD18, for
example), T lymphocyte activation (CD80/CD86 and CD28; CD25) or function (CD2, lympho‐
cyte function-associated antigen 3 (LFA-3) and cytotoxic T-lymphocyte antigen 4 CTLA-4) are
now being used with very good results [8]. However, in the case of T. cruzi infection, the
inflammatory response is very important to control parasite burden and to maintain the
immunological equilibrium during the infection. This means that an effective treatment would
have to be specific enough to silence the pathogenic components of the immune system but
still allow a protective response, especially to the heart. The importance of inflammation in the
control of the infection is illustrated by a number of experimental approaches that block normal
T cells ontogeny/development (infected nude nu/nu, RAG-/-, and thymectomized mice),
endothelial transmigration (blockage of adhesion molecules such as ICAM-1 and CD11a), or
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function (IFN-γ-/- and perforin-/- mice) [28, 29, 25]. In all these models, after T lymphocyte
inactivation, the infection was much more aggressive with higher mortality rates and increased
blood and intracellular parasitemia. Previous results indicate that this delicate balance
between an efficient or harmful inflammatory response relies on multiple aspects of the normal
physiology of T lymphocytes, and these may be targeted for future therapeutic strategies.
7. T lymphocyte-based possible targets for treating T. cruzi-induced
myocarditis
7.1. T lymphocytes senescence
Immunological  senescence of  memory T lymphocytes is  a  very interesting aspect  of  the
immune response against pathogen-based and sterile inflammation in general, not only in
T. cruzi  induced myocarditis. Normal temporary exposure of naïve T cells to antigens in
an appropriate context of activation signals leads to cellular proliferation and differentia‐
tion into effector and memory T cells. Memory T lymphocytes are generated in much smaller
quantities and are retained for longer periods of time to fight against a potential  subse‐
quent exposure to the same antigen, eliciting a more rapid and effective response. Howev‐
er,  prolonged  exposure  of  T  lymphocytes  to  pathogen-derived  antigens  or  endogenous
danger signals leads to the accumulation of a heterogeneous memory T cell population with
unique  characteristics  regarding  the  phenotypic  profile  and  functional  activities.  These
memory T cells are generally regarded as CD8+/CD28- (or CD8+/CD57+) T cells, as the loss
of CD28 is counterbalanced by the expression of CD57 in this population [30]. The loss of
CD28 and gain  of  CD57 expression on T  cells  during persistent  immune stimulation is
characteristic  of  humans  and  non-human primates  but  probably  not  of  mice.  Although
CD8+/CD28-  T cells are seen in mice, they are not the result of chronic antigenic stimula‐
tion, do not express CD57 and represent a distinct subset of naturally occurring CD8+  T
cells. Amongst this population (CD8+/CD28-), there is a sub population of memory T cells
that  was  described to  be  increased in  severe  T.  cruzi-induced myocarditis  (CD8+/CD27-/
CD28-)  and this particular phenotype is expressed by cells that are at the latest stage of
memory activation. This means that they are closest to memory terminal differentiation and
senescence, differentiated to a point where co-stimulatory signals are no longer sufficient
to induce normal memory T cell response. It seems that the phenotypic sequence of memory
stages is  CD27+/CD28+;  CD27-/CD28+  or  CD27+/CD28-;  and CD27-/CD28-  for  cells  that  are
‘early’, ‘intermediate’ and ‘late’ stages of memory CD8+ T cells, respectively [31].
It was first shown that chronic patients with cardiac enlargement and clinical or radiological
evidence of heart failure have a higher frequency (%) of late activated memory CD8+ T cells
(CD27-/CD28-) in blood, when compared with patients that present mild cardiac alterations
[32]. Accordingly, the frequency of early activated CD27+/CD28+/CD8+ T cells in the total
memory CD8+ T cell population decreases, as disease becomes more severe. The authors
hypothesize that there is a gradual clonal exhaustion of this sub-population of early activated
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memory CD8+ T cells, perhaps as a result of continuous antigenic stimulation by persistent
parasites
It is still not known if there is indeed a causative relation between the increase of CD8+/CD27-/
CD28- memory cells in chronic T. cruzi infected patients and the more severe clinical status of
myocarditis and cardiac dysfunction. However, it is interesting to speculate that these cells
could have a suppressive activity over protective CD8+ T lymphocytes (Fig. 1). If this is true,
the death or functional suppression of protective CD8+ T lymphocytes observed in severely
affected patients could be a result of late stage senescent memory T cells. A similar interaction
has been described for tumor cells [33]. In this case, CD8+/CD27-/CD28- have a suppressive
activity over the proliferation of (protective) effector T lymphocytes, and this function requires
cell-to-cell contact. In fact, T. cruzi specific late stage memory CD4+/CD27-/CD28- T lympho‐
cytes are also increased in more severely affected cardiac patients, when compared with
patients with mild myocarditis, as observed in the CD8+ compartment [34]. It is important to
highlight that these senescent memory T cells, which can be CD8 or CD4 T cells, are distinct
from CD4+ T regulatory (TReg) cells that express the transcriptional factor FoxP3 [35].
Although this immunological characteristic of memory T lymphocytes senescence would
probably be hard to be used as a target for treatment, these peripheral blood mononuclear cells
(PBMC) markers could be used as a predictive tool for the severity of potentially developing
myocarditis in chronic patients in the undetermined stage.
7.2. Chemokines and T lymphocyte migration to infected myocardium
One very important aspect of the myocarditis induced by T. cruzi infection is to know which
chemotactic mediators are produced by the cardiac tissue and which effector cells migrate to
the tissue. Ultimately, the cardiac microenvironment will determine the balance between the
control of parasite growth and avoidance of inflammatory secondary damage and cardiac
dysfunction. In this regard, it was shown that cardiomyocytes do not act as passive players
facing the infection. Indeed, these cells become activated and secrete NO, through the activity
of the induced NO synthase (iNOs) enzyme; chemokines; and pro-inflammatory cytokines
[36]. These mediators destroy intracellular parasites or act on inflammatory cells in the vicinity
[37]. Among these mediators, we find tumor necrosis factor (TNF), interleukin (IL)-1beta
(IL-1β), and chemokines growth-related oncogene (GRO or CXCL1), monokine induced by
interferon-gamma (MIG or CXCL9), macrophage inflammatory protein-2 (MIP-2), interferon-
gamma-inducible protein (IP-10 or CXCL10), monocyte chemotactic protein (MCP-1 or CCL2),
and regulated and normal T cell expressed and secreted (RANTES or CCL5). Moreover,
inflammatory cells composing cardiac inflammatory foci also produce cytokines and chemo‐
kines, composing an environment that is rich in pleiotropic inflammatory mediators.
Chemokines are small (8-14 kDa) constitutive or inducible inflammatory cytokines, compris‐
ing four protein subfamilies (CXC or α, CC or β, C or γ, and CX3C or δ) that act through trans-
membrane spanning G protein-coupled receptors expressed on the surface of several leukocyte
and other cells. Chemokines are mostly known by their chemotactic capacity, but they also
play a role in angiogenesis; dendritic cell maturation; tumor growth and metastasis; and others.
Diagnosis and Treatment of Myocarditis54
These functions are mostly mediated by the activation of many protein kinases, increased
cytoplasmic Ca++ and mainly activation of transcription factors [38].
Figure 1. Cardiac pathogenic and protective T lymphocytes in Trypanosoma cruzi infection. Myocarditis and cardio‐
myocyte damage are considered pivotal in the progression of cardiac dysfunction. Therefore, the balance between
pathogenic and protective T lymphocyte sub populations may determine the severity of the cardiac pathology in‐
duced by the infection. Senescent (1) CD4 and CD8 late stage memory T lymphocytes (CD27-/CD28-) are enriched in
blood of patients more severely affected. It has been hypothesized that these cells act as suppressor cells over protec‐
tive T lymphocytes, as observed in some tumors. CD4+ T lymphocytes secreting IL-17 (Th17) (2) are protective for T.
cruzi-induced myocarditis, as the inactivation of this cytokine leads to increased susceptibility and cardiac inflammato‐
ry infiltration. Some directly pathogenic T lymphocyte sub populations are enriched in the heart of patients with more
severe myocarditis. This was observed for T lymphocytes expressing high levels of the chemokine receptor CCR5 (3), T
lymphocytes (and maybe other cells, like macrophages) expressing Fas (4) and possible other pathogenic T lympho‐
cytes that remain to be uncovered (5). T regulatory (TReg) lymphocytes apparently do not play a role in the control of
myocarditis in murine infection (6), but are enriched in blood of chronic asymptomatic ones (6), when compared with
cardiac symptomatic patients. Although still not known what sub populations of T lymphocytes are suppressed by
TReg lymphocytes, we suggest some sub populations in the diagram. (?) Means not experimentally tested.
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In  the  case  of  non-experimental  infection with  T.  cruzi,  it  was  found that  patients  with
severe  chronic  chagasic  cardiomyopathy  have  higher  levels  of  TNF  and  CCL2  (CCR2
ligand),  when  compared  with  patients  with  mild  cardiac  dysfunction  [39].  Conversely,
enhanced  expression  of  CCR5,  a  chemokine  receptor  for  some  CC  chemokines  (CCL3/
MIP1α, CCL4/MIP-1β, CCL5/RANTES), and CXCR3 was found in PBMC from patients with
cardiomyopathy, when compared with asymptomatic patients [40]. Taken together, these
data  suggest  that  not  only  cytokines,  but  also  chemokines  and  their  receptors,  may  be
involved in the cardiac pathogenesis associated with T. cruzi infection, especially CCR5high
T  lymphocytes  (Fig.  1),  what  could  be  explored  in  future  therapeutic  designs.  This  is
illustrated by human polymorphisms that show that migration of CCR5+ T lymphocytes to
the  heart  is  associated  with  a  more  severe  human  and  experimental  cardiomyopathy.
Namely,  studies  of  CCR5  59029A/G  gene  polymorphism  in  Peruvian  and  Venezuelan
patients revealed that the G allele, which reduces CCR5 expression, is found more frequently
in asymptomatic than in symptomatic chronic patients [41].
The idea that some CC chemokines, and particularly CCR5 receptor, could be involved in the
pathogenesis of T. cruzi-induced myocarditis has been tested in experimental infection [42,
43]. Chronically infected mice were treated with N-terminal-methionylated RANTES (Met-
RANTES), a selective CCR1/CCR5 antagonist, and the treatment led to a reduction in the
number of cardiac parasite nests, fibrosis, and cardiomyocytes damage, as ascertained by
creatine kinase (CK-MB) levels in blood. Moreover, there was an increase in the expression of
connexin 43, a major component of gap junctions in the heart, and iNOs. These results are very
important as a possible alternative for myocarditis treatment, especially if we consider that
these mice were treated in the chronic phase, when the cardiac dysfunction is many times
irreversible.
7.3. Th17 immune response
When a naïve CD4+ T lymphocyte encounters an antigen presenting cell (APC), it has the
potential to differentiate into a T (helper) h1; Th2; Th3 (secreting mostly TGF-β and IL-10 and
usually found in mucosa); inducible regulatory T lymphocyte (iTReg - cited in a following
item); or Th17 lymphocyte. This commitment is mostly based on the cytokines secreted by the
APC, which will interact with cognate cytokine receptors on the lymphocyte’s surface and lead
to the activation of the JAK/STAT (Janus kinases/Signal Transducers and Activator of Tran‐
scription proteins) pathway. The differentiation of cellular subtypes induced by the cytokines
is mostly based on different combinations of JAK proteins and STAT transcription factors. In
mammals, there are four members of the JAK family (JAK1, JAK2, JAK 3 and Tyk2) and seven
members of the STAT family (STAT1-4; 5A; 5B; 6). These signaling molecules will ultimately
induce the expression, or repression, of many genes that will orchestrate the final cellular
differentiation, including the panel of cytokines that will be secreted by the final lineage
committed CD4+ T lymphocyte [44]. Th1 cells are mainly induced by IL-12 and produce mostly
IFN-γ, TNF-α, IL-2 and IL-12; while Th2 cells are mainly induced by IL-4 and produce IL4,
IL5, IL-6, IL-10, and IL-13. In humans, the cytokines that instruct Th17 cell lineage development
likely include IL-6; IL-21; IL-23; and IL-1β, with TGF-β playing a role in the suppression of Th1
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cell lineage commitment. Then, STAT3 is necessary for gene clusters transcription, ultimately
leading to the expression of their lineage-defining transcription factors, which are some
retinoid orphan receptors (ROR). Th17 cells secrete mainly IL-17A, IL-17F, IL-21, IL-22, IFN-
γ, IL-4, IL-10, IL-9, and IL-26 [45] and were initially described as destructive cells that induced
autoimmunity and inflammatory diseases. However, more recently it became clear that they
also play a role as protective cells, at least in the case of pathogenic infection with C. albicans
and S. aureus.
Targeting IL-17 alone with Secukinumab (AIN457) or Ixekizumab, both fully human neutral‐
izing antibodies against IL-17A, has been shown to lead to clinical improvement in patients
with psoriasis, rheumatoid arthritis, and other auto-immune diseases. On the other hand, in
the case of experimental T. cruzi infection, Th17 response appears to be protective against the
infection (Fig. 1). IL-17A-deficient mice infected with T. cruzi have a lower survival rate, display
prolonged and higher parasitemia, multiple organ failure, and increased markers of tissue
injury when compared with infected C57BL/6 (wild type) mice [46]. Moreover, mice treated
with neutralizing antibodies against IL-17 showed signs of more severe myocarditis, with more
mononuclear cells migrating to the tissue [47]. According to these results, IL-17 secretion plays
a role in the control of the infection and, differently from other inflammatory diseases, should
not be treated by neutralizing IL-17.
7.4. Cell membrane fas/fas-L interaction
Fas agonistic stimulus was formerly a synonym of apoptosis. However, Fas/Fas-L interaction
can no longer be inextricably associated with cell death. Fas-linked downstream pathways can
lead to cellular survival; proliferation and/or activation, cytokines and chemokines secretion;
genes transcription; inflammatory regulation; etc [8]. The Fas molecule is a type I membrane
protein that belongs to the tumor necrosis factor (TNF) family, and is normally distributed as
monomers on cell surface. These monomers spontaneously and temporarily group into non
signaling oligomers, but agonistic activation through trimers of Fas-L leads to conformational
changes and trimerization/coupling of Fas to intracellular signaling pathways. With regards
to apoptosis, it has been demonstrated that two adjacent trimeric Fas complexes are sufficient
to induce a functional response [48]. Alternative splicing of Fas generates soluble molecules
(sFas) that retain the ability of binding to Fas-L and inhibit Fas-L-dependent responses. Fas-L
is a type II membrane protein belonging to the TNF receptor family and can also exist as a
membrane (mFas-L) or a soluble molecule (sFas-L). SFas-L is generated by matrix metallo‐
proteinase (MMP7) and sFas-L monomers have no proapoptotic activity, as long as they do
not induce Fas trimerization. On the other hand, sFas-L shows proinflammatory functions,
acting as a strong chemotactic factor for polymorphonuclear cells, although not involved in
neutrophils activation [8].
Many groups have published that Fas activation in the heart of experimental models or human
patients leads to enhanced inflammation, cardiac dysfunction, and hypertrophy. Accordingly,
lack of Fas/Fas-L interaction results in less severe myocarditis and cardiac involvement. To
date, it has been shown that murine myocarditis induced by coxsackievirus B3 was reduced
in mice treated with anti-Fas-L, in Fas-deficient mice (lpr/lpr), and in Fas-L-deficient mice (gld/
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gld). In infected wild type mice, γδ T lymphocytes selectively kill protective Th2 CD4+ T cells
through a Fas-based pathway, enriching the inflamed heart in pathogenic Th1 cells [49]. When
the Fas/Fas-L pathway is silenced, Th2 cells are enriched in the organ, what counterbalances
the activity of Th1 cells and reduces cardiac inflammatory response and damage [50].
With regards to a possible molecular therapy for myocarditis that modulates Fas/Fas-L
interaction, a likely alternative would involve the blockage of the pathway, which however is
very complicated. The injection of competitive ligands or neutralizing Abs can mislead to
general Fas inactivation and important side effects could be induced by indiscriminate lack of
apoptosis, such as tumor growth and metastasis, and reduced normal turnover of cells.
Moreover, the Fas/Fas-L pathway is coupled to many different cytoplasmic signaling mole‐
cules that lead to a number of different cellular responses in different populations. This makes
very difficult to predict what kind of side effects could be observed [8].
In the case of myocarditis induced by T. cruzi infection, we observed that infected gld/gld mice
have a very modest cardiac inflammatory infiltration, when compared with infected wild type
mice, suggesting a pathogenic role for Fas-bearing cells (Fig. 1)However, despite this promis‐
ing finding, we observed that both lineages have high mortality rates [51]. Apparently, the
death of infected gld/gld mice is due to a more severe and earlier renal inflammatory infiltra‐
tion/damage, while the death of infected wild type mice seems to be mostly related to myo‐
carditis and cardiac dysfunction [52]. There are complex organ-specific modulatory roles
played by Fas/Fas-L interaction, and more studies are necessary to approach this pathway
therapeutically. If possible, one of the most promising options would be the injection of non-
agonistic humanized Abs against Fas to avoid cardiomyocytes death through this pathway [8].
This would probably not induce bystander cell death or trigger the proinflammatory activities
of this pathway. Another alternative could be the inactivation of downstream signaling
molecules of the Fas pathway to reduce cardiac inflammation, hypertrophy, and dysfunction.
Inhibition of Fas-1,4,5-inositol triphosphate cascade with genistein, xestospongin C, or
herbimycin A prevented apoptotic and non-apoptotic cardiac dysfunction. This pathway is
functionally interconnected to the PI3K/AKT/GSK3beta pathway that acts in concert to cause
nuclear factor of activated T cells (NFAT) nuclear translocation. The elucidation of these Fas-
based biochemical pathways responsible for unwanted outcomes in the cardiac function may
help to design more efficient therapies in the future. On the other hand, it is noteworthy that
any prolonged treatment blocking the Fas pathway could be dangerous.
7.5. Regulatory T cells
Regulatory T cells (TReg) were first described by Sakagushi et al [53] and consist of a thymus-
derived sub-population of T lymphocytes (natural TReg cells) that have suppressive activity
over effector peripheral T cells, avoiding autoimmunity. However, TReg cells can be generated
in the periphery, and these cells are known as induced TReg cells. TReg cells were phenotyp‐
ically described as CD4+/CD25+ and use a molecular arsenal to silence peripheral effector T
cells, such as membrane IL-10 and TGF-β; CTLA-4; and others [54].
In the particular case of T. cruzi-induced myocarditis, there is a controversy regarding these
regulatory T cells when considering animal models and results obtained from human subjects
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(Fig 1). Apparently, in mice these cells have no regulatory function over effector cardiac T cells
[55]. On the other hand, it was observed that these cells are enriched in chronic asymptomatic
patients, when compared with chronic symptomatic ones [56]. A better discrimination of the
phenotype of these cells shows that CD4+/Foxp3+/CD25high TReg cells from chronic non-
cardiomyopathy patients produce higher levels of IL-17, IL-10 and granzyme B. This correlates
with increased apoptosis of effector (pathogenic) cardiac T cells and maintenance of a better
cardiac function [57]. Regulatory T cells would probably not be targeted for myocarditis
therapy, but instead could be used as a prognostic marker for cardiac dysfunction.
8. Conclusion
All molecular pathways cited here could potentially be used to silence pathogenic T lympho‐
cyte sub-populations that lead to myocarditis, or as a predictive tool for patients that have the
potential to develop myocarditis and cardiac dysfunction. Despite this targeted modulation
of sub-compartments of the immune system, the capacity of controlling the infection should
in general terms be preserved to ensure infection resistance.
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